In the latest trading session, 29.11 million Oncolytics Biotech, Inc (NASDAQ:ONCY) shares changed hands as the company’s beta touched 1.27. With the company’s most recent per share price at $0.81 changing hands around $0.0 or -0.62% at last look, the market valuation stands at $62.04M. ONCY’s current price is a discount, trading about -88.89% off its 52-week high of $1.53. The share price had its 52-week low at $0.71, which suggests the last value was 12.35% up since then. When we look at Oncolytics Biotech, Inc’s average trading volume, we note the 10-day average is 0.39 million shares, with the 3-month average coming to 468.20K.
Analysts gave the Oncolytics Biotech, Inc (ONCY) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.17. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ONCY as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Oncolytics Biotech, Inc’s EPS for the current quarter is expected to be -0.13.
Oncolytics Biotech, Inc (NASDAQ:ONCY) trade information
Instantly ONCY was in red as seen in intraday trades today. With action -11.97%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -11.91%, with the 5-day performance at -11.97% in the red. However, in the 30-day time frame, Oncolytics Biotech, Inc (NASDAQ:ONCY) is -3.67% down. Looking at the short shares, we see there were 2.81 million shares sold at short interest cover period of 3.51 days.
Oncolytics Biotech, Inc (ONCY) estimates and forecasts
Data shows that the Oncolytics Biotech, Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -24.77% over the past 6 months, a 3.33% in annual growth rate that is considerably lower than the industry average of 16.70%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 18.01%. The 2025 estimates are for Oncolytics Biotech, Inc earnings to decrease by -1.84%.
ONCY Dividends
Oncolytics Biotech, Inc is expected to release its next quarterly earnings report in February.
Oncolytics Biotech, Inc (NASDAQ:ONCY)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 3.82% of Oncolytics Biotech, Inc shares while 1.76% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 1.83%. There are 1.76% institutions holding the Oncolytics Biotech, Inc stock share, with INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC the top institutional holder. As of 2024-06-30, the company held 0.2637% of the shares, roughly 0.2 million ONCY shares worth $0.2 million.
SEEDS INVESTOR LLC holds the second largest percentage of outstanding shares, with 0.2524% or 0.19 million shares worth $0.19 million as of 2024-06-30.
With 41.94 shares estimated at $33541.0 under it, the former controlled 0.05% of total outstanding shares.
